New Treatment for Advanced Neuroblastoma
Author Information
Author(s): Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V, Troncone L, Mastrangelo R
Primary Institution: Dept. Nuclear Medicine, Catholic University, Rome, Italy
Hypothesis
Can a new therapeutic model combining multiple drug chemotherapy and 131-I-MIBG improve outcomes in advanced neuroblastoma?
Conclusion
The study found a high percentage of major responses in patients with advanced neuroblastoma after a single course of combined therapy with minimal toxicity.
Supporting Evidence
- 12 patients had a partial response, 1 had a mixed response, and 3 had stable disease in the resistant group.
- In the group treated at diagnosis, 2 had a partial response, 1 had a complete response, and 2 had very good partial responses.
- No extra-medullary toxicity was observed in any patient.
Takeaway
Doctors tried a new way to treat kids with a tough cancer called neuroblastoma, and it worked really well without making them very sick.
Methodology
The study involved 21 patients treated with a combination of chemotherapy and 131-I-MIBG, with responses monitored after 4-6 weeks.
Limitations
The study is a pilot with a small sample size and short follow-up period.
Participant Demographics
Patients aged 1 to 8 years with good 131-I-MIBG uptake.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website